Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management Jul 11, 2022 08:40PM
Maxim Group Upgrades Mesoblast Limited (MESO) to Buy Apr 7, 2021 07:57AM
Mesoblast Limited (MSB:AU) (MESO) PT Lowered to $18 at Maxim Group, After Receiving FDA Complete Response Letter Oct 2, 2020 01:26PM
Mesoblast (MESO) Has Numerous Catalysts Ahead - Maxim Feb 21, 2019 07:59AM
Mesoblast Limited (MESO) PT Raised to $16 at Maxim Group Jul 18, 2018 07:46AM


Jun 7, 2018 01:53PM Mesoblast (MESO) Upcoming Data Readouts Should Boost Valuation - Maxim
Apr 10, 2017 07:40AM Maxim Group Reiterates Buy Rating and $14 PT on Mesoblast Limited (MESO); 'Successful Interim Analysis of Efficacy Endpoint in Pivotal Heart Failure Trial'
Mar 31, 2017 07:46AM Maxim Group Reiterates Buy Rating and $14 PT on Mesoblast Limited (MESO); 'Locking the Database Up for Interim Analysis'
Mar 15, 2017 08:08AM Maxim Group Reiterates Buy Rating and $14 PT on Mesoblast (MESO) Following Positive Data on Phase 2 Mesenchymal Precursor Cells Trial
Mar 7, 2017 07:43AM Maxim Group Reiterates Buy Rating and $14 PT on Mesoblast (MESO) Following MSC-100IV Fast Track Designation
Jul 5, 2016 08:51AM Mesoblast (MESO): Was Teva Ever There? - Maxim Group
Dec 31, 2015 07:40AM Mesoblast Limited (MESO) PT More Than Doubled at Maxim Group